LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Meridian Showcases Innovative Solutions for Molecular Diagnostics and Immunoassays

By LabMedica International staff writers
Posted on 11 Nov 2024
Image: Meridian is presenting its innovative solutions in molecular and immunoassay reagents at MEDICA 2024 (Photo courtesy of Meridian)
Image: Meridian is presenting its innovative solutions in molecular and immunoassay reagents at MEDICA 2024 (Photo courtesy of Meridian)

Meridian Bioscience (Cincinnati, OH, USA) is presenting its innovative solutions in molecular and immunoassay reagents that are designed to simplify assay design, eliminate cold-chain logistics, and improve sustainability. The company is also highlighting its large portfolio of antigens, antibodies, blockers, molecular enzymes, nucleotides, and optimized mixes for qPCR, isothermal amplification, and NGS applications for the IVD industry.

Meridian’s glycerol-free, high-concentration molecular reagents, and services enable the development of ambient-temperature stable assays, eliminating the need for cold chain logistics and ensuring robust and seamless supply chains. This reduces energy consumption in transit and storage as well as minimizes packaging requirements, particularly the use of refrigerant, dry ice, and expanded polystyrene foam. Meridian’s extraction-free, low-temperature molecular solutions streamline workflows by eliminating the need for multiple reagent-based extraction steps and reducing the overall energy consumption required for high-temperature processes. Streamlined workflows with fewer steps result in faster turnaround times and increased throughput, reducing operational energy and resource use. Additionally, Meridian’s animal-free recombinant alternatives for immunoassays (blockers, antibodies, and antigens) can offer greater versatility and reproducibility over animal immunization, ensuring continuity of supply while alleviating ethical concerns.

Meridian is highlighting its recently launched glycerol-free NGS enzymes, further establishing the company as a leader in developing innovative, eco-conscious, and cost-effective components for diagnostic assay developers. Visitors to Meridian’s booth at the show can also learn about the company’s introduction of the market’s first innovative lyophilized Next-Generation Sequencing (NGS) library preparation kit. This revolutionary lyophilized NGS library preparation kit, designed initially for sequencing by synthesis (SBS) protocols, marks a breakthrough in stabilizing the library preparation process at room temperature. The pioneering kit can be transported and stored at ambient temperature and contains ready-to-use lyophilized reactions to simplify the end-repair, A-tailing, ligation, and library amplification steps of most sequencing protocols. By eliminating the requirement for cold-chain shipping and storage, Meridian’s innovative kit not only simplifies logistical and environmental challenges but also significantly reduces carbon emissions and operational costs, thereby streamlining the entire NGS workflow.

Related Links:
Meridian Bioscience

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more